Novel Adenovirus Vectors
AssigneeIsis Innovation Limited
InventorsSimon Draper, Arturo Reyes, Saranya Sridhar, Adrian Hill, Sarah Gilbert, Anna Goodman
Life of this patent
Estimating the term…
Abstract
An adenoviral vector comprising a promoter further comprising a fragment of the 5′ untranslated region of the CMV IE1 gene including intron A and a nucleic acid sequence encoding a pathogen or tumour antigen for use as a medicament.
Claims33
An adenoviral vector comprising a promoter and a nucleic acid sequence encoding a pathogen or tumour antigen under the control of said promoter, wherein said promoter comprises the regulatory element and enhancer of the CMV IE1 promoter an a fragment of the 5′ untranslated region of the CMV IE1 gene including intron A, and wherein said antigen is not a murine malaria parasite antigen.
(canceled)
11-13. (canceled)
15-32. (canceled)
A product, combination or kit comprising;
- a) a priming composition comprising an adenoviral vector, comprising a promoter and a nucleic acid sequence encoding a pathogen or tumour antigen under the control of said promoter, wherein said promoter comprises the regulatory element and enhancer of the CMV IE1 promoter and a fragment of the 5′ untranslated region of the CMV IE1 gene including intron A and
- b) a boosting composition comprising a recombinant pox virus vector, said pox virus vector further comprising at least one nucleic acid sequence encoding a pathogen or tumour antigen which is the same as at least one antigen of the priming composition.
(canceled)
(canceled)
(canceled)
42-44. (canceled)
48-58. (canceled)
62-63. (canceled)
Dependencies are inferred from the claim text.